International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-5 doi: https://doi.org/10.5281/zenodo.13903148
Original Research Article
Platelet Indices as a Predictive Marker in Type 2 Diabetes Complications: Micro Versus Macro Vascular
Published
Oct. 8, 2024
Abstract

Background: Platelet dysfunction is implicated in the pathogenesis of diabetic complications. This study investigated the potential of platelet indices as predictive markers for complications in type 2 diabetes mellitus (T2DM). Methods: In this prospective observational study, 95 T2DM patients were followed for one year. Platelet indices, including Mean Platelet Volume (MPV), Platelet Distribution Width (PDW), and Plateletcrit (PCT), were measured at baseline and every three months. The development of microvascular and macrovascular complications was monitored. Results: Significant increases in all platelet indices were observed over the study period (p < 0.05). MPV showed the strongest correlation with HbA1c (r = 0.42, p < 0.01). ROC curve analysis revealed that MPV had the highest predictive value for both microvascular (AUC 0.76, p < 0.001) and macrovascular complications (AUC 0.79, p < 0.001). In multivariate analysis, MPV was an independent predictor of microvascular (OR 1.82, 95% CI 1.35-2.45, p < 0.01) and macrovascular complications (OR 2.13, 95% CI 1.56-2.91, p < 0.01). Conclusion: Platelet indices, particularly MPV, show promise as predictive markers for complications in T2DM, with a slightly stronger association with macrovascular complications. These findings suggest that platelet indices could potentially enhance risk stratification in diabetic patients

Recommended Articles
Loading Image...
Volume-5, Issue-5
Citations
2129 Views
196 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved